Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0023688,
umls-concept:C0030956,
umls-concept:C0085358,
umls-concept:C0205349,
umls-concept:C0243192,
umls-concept:C0330390,
umls-concept:C0524637,
umls-concept:C1305923,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1514873,
umls-concept:C1546857,
umls-concept:C1556066,
umls-concept:C1619636,
umls-concept:C1706438,
umls-concept:C2698600
|
pubmed:issue |
12
|
pubmed:dateCreated |
1997-2-4
|
pubmed:abstractText |
T cell activation is triggered by the specific recognition of cognate peptides presented by MHC molecules. Altered peptide ligands are analogs of cognate peptides which have a high affinity for MHC molecules. Some of them induce complete T cell responses, i.e. they act as agonists, whereas others behave as partial agonists or even as antagonists. Here, we analyzed both early (intracellular Ca2+ mobilization), and late (interleukin-2 production) signal transduction events induced by a cognate peptide or a corresponding altered peptide ligand using T cell hybridomas expressing or not the CD8 alpha and beta chains. With a video imaging system, we showed that the intracellular Ca2+ response to an altered peptide ligand induces the appearance of a characteristic sustained intracellular Ca2+ concentration gradient which can be detected shortly after T cell interaction with antigen-presenting cells. We also provide evidence that the same altered peptide ligand can be seen either as an agonist or a partial agonist, depending on the presence of CD8beta in the CD8 co-receptor dimers expressed at the T cell surface.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD8,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0014-2980
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2999-3007
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8977296-Animals,
pubmed-meshheading:8977296-Antigen Presentation,
pubmed-meshheading:8977296-Antigens, CD8,
pubmed-meshheading:8977296-Calcium,
pubmed-meshheading:8977296-Cell Line,
pubmed-meshheading:8977296-Interleukin-2,
pubmed-meshheading:8977296-L Cells (Cell Line),
pubmed-meshheading:8977296-Ligands,
pubmed-meshheading:8977296-Mice,
pubmed-meshheading:8977296-Peptides,
pubmed-meshheading:8977296-Signal Transduction,
pubmed-meshheading:8977296-T-Lymphocytes, Cytotoxic
|
pubmed:year |
1996
|
pubmed:articleTitle |
The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist.
|
pubmed:affiliation |
Centre d'Immunologie INSERM/CNRS de Marseille-Luminy, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|